Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man

P. Masturzo, A. de Maria, G. Murialdo, M. L. Bonura, C. Zauli, A. Polleri

Research output: Contribution to journalArticle

Abstract

The effect of benserazide administration on the secretion of GH, PRL, and TSH has been considered as an index of dopamine regulatory actions. Nine acromegalic patients and nine normal subjects were given a single 125 mg oral dose of benserazide, and serum GH, PRL, and TSH were determined by RIA methods every 30 min for 4 h. Benserazide did not alter GH values either in normal subjects or in acromegalic patients. A significant increase of serum PRL was found in both groups, and the increase was similar in normoprolactinemic and in hyperprolactinemic acromegalic patients. A significant increase in TSH levels was found only in acromegalic patients. Thus, a decrease in dopamine outside the blood-brain barrier did not affect GH secretion, whereas PRL secretion was changed in the acromegalic as well as in the control group.

Original languageEnglish
Pages (from-to)378-381
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume61
Issue number2
Publication statusPublished - 1985

Fingerprint

Benserazide
Thyrotropin
Prolactin
Growth Hormone
Dopamine
Blood-Brain Barrier
Serum
Control Groups

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Masturzo, P., de Maria, A., Murialdo, G., Bonura, M. L., Zauli, C., & Polleri, A. (1985). Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man. Journal of Clinical Endocrinology and Metabolism, 61(2), 378-381.

Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man. / Masturzo, P.; de Maria, A.; Murialdo, G.; Bonura, M. L.; Zauli, C.; Polleri, A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 61, No. 2, 1985, p. 378-381.

Research output: Contribution to journalArticle

Masturzo, P, de Maria, A, Murialdo, G, Bonura, ML, Zauli, C & Polleri, A 1985, 'Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man', Journal of Clinical Endocrinology and Metabolism, vol. 61, no. 2, pp. 378-381.
Masturzo, P. ; de Maria, A. ; Murialdo, G. ; Bonura, M. L. ; Zauli, C. ; Polleri, A. / Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man. In: Journal of Clinical Endocrinology and Metabolism. 1985 ; Vol. 61, No. 2. pp. 378-381.
@article{d558a7f830fd4a3aa2565db64ed68282,
title = "Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man",
abstract = "The effect of benserazide administration on the secretion of GH, PRL, and TSH has been considered as an index of dopamine regulatory actions. Nine acromegalic patients and nine normal subjects were given a single 125 mg oral dose of benserazide, and serum GH, PRL, and TSH were determined by RIA methods every 30 min for 4 h. Benserazide did not alter GH values either in normal subjects or in acromegalic patients. A significant increase of serum PRL was found in both groups, and the increase was similar in normoprolactinemic and in hyperprolactinemic acromegalic patients. A significant increase in TSH levels was found only in acromegalic patients. Thus, a decrease in dopamine outside the blood-brain barrier did not affect GH secretion, whereas PRL secretion was changed in the acromegalic as well as in the control group.",
author = "P. Masturzo and {de Maria}, A. and G. Murialdo and Bonura, {M. L.} and C. Zauli and A. Polleri",
year = "1985",
language = "English",
volume = "61",
pages = "378--381",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man

AU - Masturzo, P.

AU - de Maria, A.

AU - Murialdo, G.

AU - Bonura, M. L.

AU - Zauli, C.

AU - Polleri, A.

PY - 1985

Y1 - 1985

N2 - The effect of benserazide administration on the secretion of GH, PRL, and TSH has been considered as an index of dopamine regulatory actions. Nine acromegalic patients and nine normal subjects were given a single 125 mg oral dose of benserazide, and serum GH, PRL, and TSH were determined by RIA methods every 30 min for 4 h. Benserazide did not alter GH values either in normal subjects or in acromegalic patients. A significant increase of serum PRL was found in both groups, and the increase was similar in normoprolactinemic and in hyperprolactinemic acromegalic patients. A significant increase in TSH levels was found only in acromegalic patients. Thus, a decrease in dopamine outside the blood-brain barrier did not affect GH secretion, whereas PRL secretion was changed in the acromegalic as well as in the control group.

AB - The effect of benserazide administration on the secretion of GH, PRL, and TSH has been considered as an index of dopamine regulatory actions. Nine acromegalic patients and nine normal subjects were given a single 125 mg oral dose of benserazide, and serum GH, PRL, and TSH were determined by RIA methods every 30 min for 4 h. Benserazide did not alter GH values either in normal subjects or in acromegalic patients. A significant increase of serum PRL was found in both groups, and the increase was similar in normoprolactinemic and in hyperprolactinemic acromegalic patients. A significant increase in TSH levels was found only in acromegalic patients. Thus, a decrease in dopamine outside the blood-brain barrier did not affect GH secretion, whereas PRL secretion was changed in the acromegalic as well as in the control group.

UR - http://www.scopus.com/inward/record.url?scp=0021805906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021805906&partnerID=8YFLogxK

M3 - Article

C2 - 4008612

AN - SCOPUS:0021805906

VL - 61

SP - 378

EP - 381

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -